Piwowarska-Bilska et al., 2022 - Google Patents
Individualization of radionuclide therapies: challenges and prospectsPiwowarska-Bilska et al., 2022
View HTML- Document ID
- 6985388285347321826
- Author
- Piwowarska-Bilska H
- Kurkowska S
- Birkenfeld B
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Currently, patient-specific treatment plans and dosimetry calculations are not routinely performed for radionuclide therapies. In external beam radiotherapy, it is quite the opposite. As a result, a small fraction of patients receives optimal radioactivity. This …
- 238000002560 therapeutic procedure 0 title abstract description 79
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ballal et al. | First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu] Lu-DOTA. SA. FAPi and [177Lu] Lu-DOTAGA.(SA. FAPi) 2 | |
| Ruigrok et al. | The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research | |
| Ersahin et al. | Targeted radionuclide therapy | |
| Rösch et al. | The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y | |
| Jang et al. | Targeted alpha-particle therapy: a review of current trials | |
| Stokke et al. | Radionuclides for targeted therapy: physical properties | |
| Sarnelli et al. | Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol | |
| Plichta et al. | Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer | |
| Danieli et al. | Personalized dosimetry in targeted radiation therapy: a look to methods, tools and critical aspects | |
| Allen et al. | Comparative radioimmunotherapy of experimental melanoma with novel humanized antibody to melanin labeled with 213Bismuth and 177Lutetium | |
| Okamoto et al. | Clinical perspectives of theranostics | |
| Piwowarska-Bilska et al. | Individualization of radionuclide therapies: challenges and prospects | |
| Stenberg et al. | Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer | |
| Chakraborty et al. | Advances in radionuclides and radiolabelled peptides for cancer therapeutics | |
| Sanli et al. | 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer | |
| Kaewput et al. | Update of PSMA theranostics in prostate cancer: current applications and future trends | |
| Ambrosini et al. | Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors | |
| Divgi et al. | Overcoming barriers to radiopharmaceutical therapy (RPT): an overview from the NRG-NCI working group on dosimetry of radiopharmaceutical therapy | |
| Allen et al. | Biodistribution of a radiolabeled antibody in mice as an approach to evaluating antibody pharmacokinetics | |
| Ladrière et al. | Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals | |
| Zoi et al. | Nuclear Medicine and Cancer Theragnostics: Basic Concepts | |
| Parent et al. | A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer | |
| Kauffman et al. | Intra-arterial delivery of radiopharmaceuticals in Oncology: current trends and the future of alpha-particle therapeutics | |
| Deshayes et al. | Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices | |
| Patel et al. | Progress in targeted alpha-particle-emitting radiopharmaceuticals as treatments for prostate cancer patients with bone metastases |